BACKGROUND AND PURPOSE: The aim of this exploratory analysis was to evaluate if a combination of MR angiography (MRA) and diffusion-weighted imaging (DWI) selection criteria can be used to identify patients with acute stroke who are likely to benefit from early reperfusion. METHODS: Data from DEFUSE, a study of 74 patients with stroke who received intravenous tissue plasminogen activator in the 3- to 6-hour time window and underwent MRIs before and approximately 4 hours after treatment were analyzed. The MRA-DWI mismatch model was defined as (1) a DWI lesion volume less than 25 mL in patients with a proximal vessel occlusion; or (2) a DWI lesion volume less than 15 mL in patients with proximal vessel stenosis or an abnormal finding of a distal vessel. Favorable clinical response was defined as an improvement on the National Institutes of Health Stroke Scale score of at least 8 points between baseline and 30 days or a National Institutes of Health Stroke Scale score </=1 at 30 days. RESULTS: Twenty-seven of 62 patients (44%) had an MRA-DWI mismatch. There was a differential response to early reperfusion based on MRA-DWI mismatch status. Reperfusion was associated with an increased rate of a favorable clinical response in patients with an MRA-DWI mismatch (OR, 12.5; 95% CI, 1.8 to 83.9) and a lower rate in patients without mismatch (OR, 0.2; 95% CI, 0.0 to 0.8). CONCLUSIONS: The MRA-DWI mismatch model appears to identify patients with stroke who are likely to benefit from reperfusion therapy administered in the 3- to 6-hour time window after symptom onset. The criteria established for the MRA-DWI mismatch model in this study require validation in an independent cohort.
BACKGROUND AND PURPOSE: The aim of this exploratory analysis was to evaluate if a combination of MR angiography (MRA) and diffusion-weighted imaging (DWI) selection criteria can be used to identify patients with acute stroke who are likely to benefit from early reperfusion. METHODS: Data from DEFUSE, a study of 74 patients with stroke who received intravenous tissue plasminogen activator in the 3- to 6-hour time window and underwent MRIs before and approximately 4 hours after treatment were analyzed. The MRA-DWI mismatch model was defined as (1) a DWI lesion volume less than 25 mL in patients with a proximal vessel occlusion; or (2) a DWI lesion volume less than 15 mL in patients with proximal vessel stenosis or an abnormal finding of a distal vessel. Favorable clinical response was defined as an improvement on the National Institutes of Health Stroke Scale score of at least 8 points between baseline and 30 days or a National Institutes of Health Stroke Scale score </=1 at 30 days. RESULTS: Twenty-seven of 62 patients (44%) had an MRA-DWI mismatch. There was a differential response to early reperfusion based on MRA-DWI mismatch status. Reperfusion was associated with an increased rate of a favorable clinical response in patients with an MRA-DWI mismatch (OR, 12.5; 95% CI, 1.8 to 83.9) and a lower rate in patients without mismatch (OR, 0.2; 95% CI, 0.0 to 0.8). CONCLUSIONS: The MRA-DWI mismatch model appears to identify patients with stroke who are likely to benefit from reperfusion therapy administered in the 3- to 6-hour time window after symptom onset. The criteria established for the MRA-DWI mismatch model in this study require validation in an independent cohort.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: L Røhl; J Geday; L Østergaard; C Z Simonsen; P Vestergaard-Poulsen; G Andersen; D Le Bihan; C Gyldensted Journal: Cerebrovasc Dis Date: 2001 Impact factor: 2.762
Authors: Peter Schramm; Peter D Schellinger; Jochen B Fiebach; Sabine Heiland; Olav Jansen; Michael Knauth; Werner Hacke; Klaus Sartor Journal: Stroke Date: 2002-10 Impact factor: 7.914
Authors: Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton Journal: Lancet Date: 2004-03-06 Impact factor: 79.321
Authors: Peter Schramm; Peter D Schellinger; Ernst Klotz; Kai Kallenberg; Jochen B Fiebach; Sonja Külkens; Sabine Heiland; Michael Knauth; Klaus Sartor Journal: Stroke Date: 2004-05-20 Impact factor: 7.914
Authors: A Dávalos; M Blanco; S Pedraza; R Leira; M Castellanos; J M Pumar; Y Silva; J Serena; J Castillo Journal: Neurology Date: 2004-06-22 Impact factor: 9.910
Authors: M Wintermark; M Reichhart; O Cuisenaire; P Maeder; J-P Thiran; P Schnyder; J Bogousslavsky; R Meuli Journal: Stroke Date: 2002-08 Impact factor: 7.914
Authors: A D Horsch; J W Dankbaar; J M Niesten; T van Seeters; I C van der Schaaf; Y van der Graaf; W P Th M Mali; B K Velthuis Journal: AJNR Am J Neuroradiol Date: 2015-04-23 Impact factor: 3.825
Authors: Bruce C V Campbell; Archana Purushotham; Soren Christensen; Patricia M Desmond; Yoshinari Nagakane; Mark W Parsons; Maarten G Lansberg; Michael Mlynash; Matus Straka; Deidre A De Silva; Jean-Marc Olivot; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis Journal: J Cereb Blood Flow Metab Date: 2011-07-20 Impact factor: 6.200
Authors: Archana Purushotham; Bruce C V Campbell; Matus Straka; Michael Mlynash; Jean-Marc Olivot; Roland Bammer; Stephanie M Kemp; Gregory W Albers; Maarten G Lansberg Journal: Int J Stroke Date: 2013-06-27 Impact factor: 5.266